Adeptrix Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate announcements from Avacta Group PLC, MHRA Confirms Registration of Lateral Flow Test

    Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that its Annual Report and Accounts for the year ended 31 December 2020 and the Notice of the 2021 Annual General Meeting are now available on the Company's website, www.avacta.com. Copies of the Annual Report and Accounts and the Notice of AGM have been posted to shareholders who have elected to receive them in paper form.   The Annual General Meeting will be held on...

Investegate announcements from Avacta Group PLC, Change of Nominated Adviser

Investegate announcements from Avacta Group PLC, Issue of Equity

  Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer® biologics and pre|CISION™ tumour targeted chemotherapies.   The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the r...